Outlook Therapeutics, Inc. cash flow statement

In fiscal 2025, Outlook Therapeutics, Inc.'s operations generated −$51.8m of cash; it spent $0 on capital projects, leaving free cash flow of −$51.8m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Outlook Therapeutics, Inc.: cash flow statement, annual
Fiscal year	2015Sept 2015	2016Sept 2016	2017Sept 2017	2018Sept 2018	2019Sept 2019	2025Sept 2025
Cash from operations	−27	−45	−16	−33	−32	−52
Depreciation and amortisation	2	2	3	3	3	0
Stock-based pay	11	12	9	2	1	9
Capital spending	9	1	0	3	0	0
Free cash flow	−36	−47	−16	−36	−33	−52
Free cash flow after stock pay	−47	−59	−24	−38	−34	−61
Shares issued	41	16	2	15	46	25

US$ millions unless shown otherwise. Fiscal quarters.

Outlook Therapeutics, Inc.: cash flow statement, quarterly
Quarter	2018 Q3Jun 2018	2018 Q4Sept 2018	2019 Q1Dec 2018	2019 Q2Mar 2019	2019 Q3Jun 2019	2019 Q4Sept 2019	2025 Q3Jun 2025	2025 Q4Sept 2025
Cash from operations	−9	−8	−10	−6	−10	−6	−12	−12
Depreciation and amortisation	1	1	1	1	1	1	0	0
Stock-based pay	0	0	1	0	−0	0	2	2
Capital spending	0	1	0	0	0	0	0	0
Free cash flow	−9	−10	−10	−6	−10	−6	−12	−12
Free cash flow after stock pay	−9	−10	−11	−7	−10	−6	−14	−14
Shares issued	—	−0	12	8	26	0	15	8

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ACRS vs OTLK COYA vs OTLK APLM vs OTLK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Outlook Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Outlook Therapeutics, Inc.